Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP3A5 genotype has a dose-dependent effect on ABT-773 plasma levels.

Clinical pharmacology and therapeutics - 1 Jun 2004

Katz David A, Grimm David R, Cassar Steven C, Gentile Maria C, Ye Xin, Rieser Matthew J, Gordon Eric F, Polzin Jill E, Gustavson Linda E, Driscoll Rita M, O'dea Robert F, Williams Laura A, Bukofzer Stanley

Abstract excerpt

BACKGROUND: The metabolizing enzyme cytochrome P450 (CYP) 3A5 is polymorphically expressed as a result of genetic variants that do not encode functional protein. Because of overlapping substrate specificity with CYP3A4 and the multidrug efflux pump P-glycoprotein, the importance of CYP3A5 genetic polymorphism for pharmacokinetics is controversial. OBJECTIVE: Our objective was to determine whether genetic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Area Under Curve
Share to Confidence Intervals

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cross-Over Studies

Share to Cytochrome P-450 CYP3A

Share to Double-Blind Method

Share to Erythromycin

Share to Genes, MDR

Share to Statistics, Nonparametric

Source

Identifiers

PMID: 15179406
DOI: 10.1016/j.clpt.2004.01.013

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP3A5 genotype has a dose-dependent effect on ABT-773 plasma levels.PMID 15179406Read ↗

Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects.Semantic proximity Read ↗

Genetic Polymorphisms of OATP Transporters and Their Impact on Intestinal Absorption and Hepatic Disposition of DrugsSemantic proximity Read ↗

Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients.Semantic proximity Read ↗

Frequencies of CYP3A5 genotypes and haplotypes in a Korean population.Semantic proximity Read ↗

Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751.Semantic proximity Read ↗

CYP3A5*3 and MDR1 C3435T are influencing factors of inter-subject variability in rupatadine pharmacokinetics in healthy Chinese volunteers.Semantic proximity Read ↗

CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy.Semantic proximity Read ↗

Factors influencing midazolam hydroxylation activity in human liver microsomes.Semantic proximity Read ↗

Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects.Semantic proximity Read ↗

The Effect of CYP3A5 and MDR1 Polymorphic Expression on Cyclosporine Oral Disposition in Renal Transplant PatientsSemantic proximity Read ↗

Functional assessment of the effects of CYP3A4 variants on acalabrutinib metabolism in vitro.Semantic proximity Read ↗

Effects of CYP3A4 polymorphisms on the plasma concentration of voriconazole.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.